FAZ-053 is under clinical development by Laekna Therapeutics Shanghai and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData, Phase I drugs for Soft Tissue Sarcoma have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FAZ-053’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FAZ-053 is under development for the treatment of advanced solid tumors including chordoma and alveolar soft part sarcoma, triple negative breast cancer. It is administered intravenously. The therapeutic candidate is a monoclonal antibody that acts by targeting programmed cell death 1 ligand 1 (PD-L1). It was under development for the treatment of non-small cell lung carcinoma, endometrial cancer and anaplastic thyroid cancer.
Laekna Therapeutics Shanghai overview
Laekna Therapeutics Shanghai, a biotech company that focused on innovative drug discovery and development. The company is headquartered in China.
For a complete picture of FAZ-053’s drug-specific PTSR and LoA scores, buy the report here.